Mpox
Also known as: Monkeypox
Methodology & AI Transparency ⓘ
Mpox Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is mpox? Mpox, which used to be called monkeypox, is a disease caused by the monkeypox virus.
- 2 Real-world patient consensus: Synonyms for Mpox (L80.8): Monkeypox (Skin & Dermatology).
- 3 Typical cash cost range: Primary evaluation for Mpox incorporates clinical dermatologic lesion in Mpox (L80.8: morphology exam) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Mpox: maintaining Affected Body Surface in Mpox (L80.8: Area (BSA /) within Clear or Almost Clear (IGA 0–1) (L80.8).
Ask our AI Specialists anything about Mpox
What Is Mpox?
What is mpox? Mpox, which used to be called monkeypox, is a disease caused by the monkeypox virus. This virus is in the same family of viruses as the smallpox virus. Mpox can be spread between animals and people, but it's mainly spread through close contact with someone who has it. It is found regularly in parts of Central, Eastern and West Africa. The virus that causes it has been found in small rodents, monkeys, and other mammals that live in these areas. Some outbreaks of mpox have affected people in many countries around the world, including the United States.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Mpox (code L80.8) is epidermal barrier filaggrin/ceramide in Mpox (L80.8: disruption), Cross-referenced with NIH MeSH (Mpox, Monkeypox), which Dermatology: Acne, Eczema, Psoriasis & Rosacea clinicians address while surveilling Affected Body Surface in Mpox (L80.8: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L80.8)).
Common Symptoms & Clinical Signs
- • Clade I is regularly found in Central and Eastern Africa. It causes more severe illness and deaths than clade II
- • Through close, personal contact with someone who has the virus: • Through direct contact with their rash, scabs, or body fluids
- • Presentation of Mpox (L80.8): persistent erythematous plaques, in Mpox (L80.8: scaly patches, pruritic)
- • Secondary Mpox clinical sign: compromised epidermal barrier in Mpox (L80.8: with dryness, fissuring,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Mpox Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L80.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Affected Body Surface in Mpox (L80.8: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L80.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Mpox (L80.8: ALT (if systemic) | Within baseline reference limits (L80.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Mpox (L80.8: & hs-CRP) | 25(OH)D 40–65 ng/mL (L80.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Mpox
Treatment selection for Mpox depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mpox)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne:: What a 241-Participant Study Found In 3 clinical trials, CAB, the only fixed-dose, triple-combination applied to the skin for acne, demonstrated ≥70% lesion reductions, with good tolerability regardless of participants' sex or age. Journal of drugs in dermatology : JDD • 2026-08-01 • Phase III Randomized Trial | N = 241 | 88/100 | PMID 42555077 ↗ |
| Cost per responder analysis of abrocitinib vs. Dupilumab: Which Works Better for Moderate to severe eczema? According to JADE COMPARE trial data, the costs per responder of abrocitinib were considerably lower than dupilumab. Italian journal of dermatology and venereology • 2024-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39250163 ↗ |
| Can This Approach Help? Inside the Latest Research on Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc Maintenance of response using reduced-dose abrocitinib 100 mg may be feasible for patients with lower baseline disease severity and strong response to abrocitinib 200 mg induction treatment. Journal of the European Academy of Dermatology and Venereology : JEADV • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38752592 ↗ |
| Can This Approach Help? Inside the Latest Research on A gold-standard blind study of the effects of 13-cis-retinoic acid on acne, sebum The decline in micro-organisms occurred after the reduction in sebum and FFA production. The British journal of dermatology • 1982-11-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 6215056 ↗ |
| Stubborn Plaque Psoriasis? A Targeted New Antibody Cleared Skin in a 461-Patient Trial The real-world benefits and safety of vunakizumab are not affected by different regions of China in patients with moderate-to-severe plaque psoriasis skin flare-ups skin flare-ups. The Journal of dermatological treatment • 2025-12-15 • Phase III Randomized Trial | N = 118 | 82/100 | PMID 41020409 ↗ |
Mpox Patient Community & “People Like Me” Threads
Filter Mpox community threads and patient logs by age, biological sex, dosage, and treatment duration.